Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2025 ,inter alia, to consider and approve 1. Unaudited financial results for ....
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts more than Nifty Microcap 250 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bal Pharma Ltd has called a Board meeting on 11 August 2025 to consider several key items. These include approval of the unaudited standalone and consolidated financial results for the quarter ended 30 June 2025 (Q1 FY26), convening the 38th Annual General Meeting, and deciding book closure dates. The Board will also consider approving a draft Employee Stock Option Plan (ESOP) for 2025 and the merger of its subsidiary Lifezen Healthcare Pvt Ltd with Bal Pharma Ltd. The trading window for designated persons and their immediate relatives is already closed from 1 June 2025 until 14 August 2025, covering the period up to 48 hours after the results are declared.
Investors should watch 11 August closely — the Q1 FY26 numbers, the new ESOP scheme, and the subsidiary merger decision could all influence short-term sentiment. A merger with a subsidiary generally simplifies the group structure but the exact terms and any share-swap ratio are not yet disclosed.